Application of ellagic acid in preparation of medicine for preventing or treating ionizing radiation injury
By regulating oxidative stress and inflammatory response with ellagic acid, a pharmaceutical formulation was prepared, which solved the problems of short half-life and large side effects of existing radiation protection agents. This achieved effective protection against ionizing radiation, alleviated oxidative damage and inflammatory response, improved stress tolerance and extended lifespan.
Patent Information
- Application Number
- CN202511364003.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-23
- Publication Date
- 2025-12-05
AI Technical Summary
Existing radiation protection agents such as amifostine have short half-lives and significant side effects, making them difficult to use widely for preventative or long-term protection. Furthermore, the potential role of ellagic acid, a natural polyphenol compound, in ionizing radiation protection remains unclear.
Ellagic acid was used to regulate oxidative stress and inflammatory response pathways and was prepared into a pharmaceutically acceptable dosage form. By scavenging reactive oxygen species, inhibiting lipid peroxidation, enhancing antioxidant enzyme activity, and promoting the expression of related genes, it can be used for ionizing radiation protection.
It can effectively alleviate oxidative damage, inflammatory response, decreased stress tolerance and shortened lifespan caused by ionizing radiation, improve stress resistance under radiation exposure, and reduce health risks.
Smart Images
Figure CN121059595A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The application belongs to the field of biological medicine and radiation protection, and relates to application of a natural polyphenol compound ellagic acid in preparation of an ionizing radiation protection drug for preventing and treating oxidative damage, inflammatory response, decreased stress tolerance, accelerated aging and shortened lifespan induced by a certain dose of ionizing radiation. BACKGROUND
[0002] With the wide application of nuclear technology in the fields of energy production, medical treatment and military, the health risks of exposure to a certain dose of ionizing radiation have greatly increased, which has caused people's serious concern about the potential health hazards. High-dose ionizing radiation can cause persistent oxidative stress and chronic inflammation in the body, cause DNA damage, immune function disorder, decreased stress tolerance, accelerate the aging process, and ultimately lead to shortened lifespan of organisms. Therefore, how to effectively protect against persistent oxidative damage and chronic inflammation induced by high-dose ionizing radiation, so as to reduce the health hazards caused by ionizing radiation exposure is one of the key scientific problems to be solved in this field.
[0003] Chemical synthesis occupies a dominant position in existing radiation protection agents, mainly including compounds such as aminomercapto family. For example, amifostine (WR-2721) developed by the U.S. Army Institute of Medicine is a sulfophosphoric drug, which mainly removes free radicals generated by ionizing radiation to reduce tissue cell oxidative damage and has a certain radiation protection effect. At present, amifostine is the only radiation protection agent approved for use in the United States. However, amifostine has the pharmacokinetic characteristics of short half-life, insufficient tissue-specific distribution, rapid metabolism, etc. in the body, resulting in a narrow protection window period and difficulty in maintaining stable effect; in addition, the drug often causes serious side effects such as hypotension, fever, nausea and vomiting, which greatly limits its wide application in preventive application or long-term protection scenarios. Due to these reasons, this type of drug has great limitations in actual application. Therefore, developing a safe, non-toxic and easily obtained radiation protection agent may be a promising strategy to prevent and reduce health hazards caused by ionizing radiation.
[0004] Ellagic acid is a natural polyphenol compound widely present in various fruits, nuts and seeds (such as pomegranate, strawberry, raspberry, walnut, almond, etc.). Some previous studies have shown that ellagic acid has the potential to prevent and treat various diseases (including diabetes, atherosclerosis, neurodegenerative diseases, even cancer, etc.). The existing radiation protectants have obvious limitations, and the natural polyphenol compound ellagic acid with antioxidant and anti-inflammatory properties may also have certain effects and potential application value in ionizing radiation protection. However, the potential protective effects of ellagic acid in reducing or alleviating oxidative damage, inflammatory response, decreased stress tolerance, accelerated aging and shortened lifespan caused by ionizing radiation exposure are not yet clear. Therefore, how to develop safe and effective new ionizing radiation protection drugs using natural polyphenol compound ellagic acid has become a problem to be solved. SUMMARY
[0005] In order to overcome the above-mentioned defects of the existing radiation protectants, the purpose of the present application is to provide the application of natural polyphenol compound ellagic acid in the preparation of drugs for preventing or treating ionizing radiation damage. The ellagic acid of the present application can alleviate the health risks of oxidative damage, inflammatory response, decreased stress tolerance, accelerated aging and shortened lifespan caused by ionizing radiation exposure by regulating key oxidative stress response and inflammatory response pathways, providing a new strategy for the health protection of ionizing radiation exposed personnel and a new transformation path for the development of radiation protection agents based on ellagic acid.
[0006] In order to achieve the above-mentioned application purposes, the present application is realized by the following technical solutions: The present application provides the application of ellagic acid in the preparation of drugs for preventing or treating ionizing radiation damage.
[0007] In the above technical solution, further, the ionizing radiation includes X-ray, alpha-ray irradiation, beta-ray irradiation, gamma-ray irradiation, neutron and heavy ion radiation.
[0008] In the above technical solution, further, the ionizing radiation damage includes oxidative damage, inflammatory response, decreased stress tolerance, accelerated aging and shortened lifespan induced by ionizing radiation.
[0009] In the above technical solution, further, the drug includes an effective amount of the above-mentioned ellagic acid and a pharmaceutically acceptable excipient.
[0010] In the above technical solution, further, the pharmaceutically acceptable excipient includes a filler, a diluent, a binder, a disintegrant and an emulsifier.
[0011] In the above technical solution, further, the drug is prepared into a pharmaceutically permissible dosage form.
[0012] In the technical scheme, further, the dosage form includes tablets, granules, oral liquid preparations, drops, injection preparations and capsule preparations.
[0013] In the technical scheme, further, the drug removes active oxygen, inhibits lipid peroxidation, enhances glutathione transferase activity and superoxide dismutase activity, promotes expression of antioxidant-related genes sod-1 、 sod-2 、 gst-1 and gst-29 immune-related genes lys-1 、 irg-1 、 irg-2 and mul-1 , thereby relieving oxidative damage, inflammatory response, stress tolerance decrease, accelerated aging and shortened lifespan caused by ionizing radiation exposure.
[0014] In the technical scheme, further, the drug containing an effective concentration of ellagic acid is administered to the subject before or after ionizing radiation exposure.
[0015] In the technical scheme, further, the drug is used for nuclear accident emergency radiation protection, secondary damage effect adjuvant therapy of radiotherapy patients and space radiation protection of astronauts.
[0016] Compared with the prior art, the present application has the following beneficial effects: The effective concentration of ellagic acid can effectively improve the stress resistance under ionizing radiation exposure by reducing oxidative damage and inflammatory response induced by ionizing radiation exposure, and relieve health risks such as accelerated aging and shortened lifespan caused by ionizing radiation exposure; specifically, the effective concentration of ellagic acid can effectively inhibit active oxygen accumulation induced by ionizing radiation exposure by enhancing superoxide dismutase and glutathione transferase activity and reducing malondialdehyde level; at the same time, the effective concentration of ellagic acid also promotes high expression of antioxidant and immune-related genes under ionizing radiation exposure, thereby enhancing antioxidant and immune response, improving stress tolerance, and reducing health risks such as accelerated aging and shortened lifespan induced by ionizing radiation exposure. Therefore, the present application has wide application in preventing or reducing health risks such as oxidative damage, inflammatory response, stress tolerance decrease, accelerated aging and shortened lifespan caused by ionizing radiation exposure. BRIEF DESCRIPTION OF DRAWINGS
[0017] In order to more clearly illustrate the embodiments of the present application, the drawings involved in the embodiments will be briefly introduced as follows.
[0018] The drawings of the present application include four drawings, Figure 1: The results of the removal of oxidative damage in C. elegans caused by ionizing radiation exposure by 200 μM ellagic acid, wherein A represents the results of active oxygen detection (active oxygen was labeled using a CM-H2DCFDA probe); B represents the results of malondialdehyde content detection; C represents the results of superoxide dismutase activity detection; D represents the results of glutathione transferase activity detection; E represents the relative expression level of sod-1 sod-2 gst-1 gst-29
[0019] Figure 2 : The results of the regulation of immune response gene expression in C. elegans under ionizing radiation exposure by 200 μM ellagic acid, wherein A represents the relative expression level of lys-1 irg-1 irg-2 mul-1
[0020] Figure 3 : The results of the alleviation of stress tolerance in C. elegans under ionizing radiation exposure by 200 μM ellagic acid, wherein A represents the average survival time under oxidative stress (100 μM juglone solution) conditions; B represents the average survival time under osmotic stress (200 mM NaCl solution) conditions; C represents the average survival time under metal stress (50 mM CdCl2 solution) conditions; D represents the average survival time under pathogen (Pseudomonas aeruginosa) stress conditions.
[0021] Figure 4 : The results of the recovery of the shortening of the lifespan of C. elegans caused by ionizing radiation exposure by ellagic acid, wherein A represents the lifespan curves of C. elegans in the 20 Gy irradiation group and the 20 Gy-200 μM ellagic acid group; B represents the lifespan curves of C. elegans in the 50 Gy irradiation group and the 50 Gy-200 μM ellagic acid group; C represents the average lifespan of C. elegans in each experimental group. DETAILED DESCRIPTION
[0022] The application will be described in detail below with reference to the embodiments, but the embodiments of the application are not limited thereto. Obviously, the embodiments described below are only part of the embodiments of the application, and other similar embodiments obtained by those skilled in the art without creative labor fall within the protection scope of the application.
[0023] In the present application, the natural polyphenolic compound ellagic acid is used for preparing a medicine for protecting or alleviating oxidative stress induced by ionizing radiation, enhancing antioxidant capacity; or for preparing a medicine for protecting or alleviating inflammatory response induced by ionizing radiation, decreasing stress tolerance, accelerating aging, and shortening lifespan; or for emergency radiation protection in nuclear accidents, adjuvant therapy for secondary damage effect of radiotherapy patients, and space radiation protection for astronauts.
[0024] The source of the ellagic acid in the present application is not particularly limited, and commercially available products known in the art can be used.
[0025] The technical solutions of the present application are further specifically described below through specific examples.
[0026] Example 1 1. Materials In the present example, the experimental model is Caenorhabditis elegans, which is purchased from the Caenorhabditis Genetic Center in the United States; and the ellagic acid is purchased from Shanghai Yuan Ye Company, with a purity of ≥98%.
[0027] In the present example, the experimental model is Caenorhabditis elegans, which is often considered an important model organism in radiation protection research because it has a clear genetic background and a high degree of homology with the human coding genome. In addition, this model is often used in aging and lifespan evaluation experiments due to its short lifespan and other characteristics.
[0028] 2. Methods 2.1 Culture of Caenorhabditis elegans Caenorhabditis elegans is cultured on standard NGM medium with defective Escherichia coli OP50 as a food source, and the culture conditions are 20℃ and a relative humidity of 60%. Specifically, synchronized eggs of Caenorhabditis elegans are obtained by a modified alkaline sodium hypochlorite treatment method, and then the eggs are transferred to NGM medium coated with OP50 to develop to the L1 larval stage for subsequent ionizing radiation exposure experiments.
[0029] 2.2 Ionizing radiation exposure experiment A 6 MVp X-ray is used as a radiation source to carry out the ionizing radiation exposure experiment. Specifically, L1 stage Caenorhabditis elegans is transferred to NGM medium coated with OP50 and placed in the center of the irradiation field, and irradiation is performed by vertical irradiation. The ionizing radiation experiment is set up in two dose groups of 20 Gy and 50 Gy. The ionizing radiation dose is calibrated and measured using a medical treatment radiation detector; the control group does not receive ionizing radiation exposure.
[0030] 2.3 Preparation of ellagic acid solution and experimental grouping Ellagic acid was dissolved in dimethyl sulfoxide (DMSO) to prepare a 40 mM DMSO stock solution, which was stored at -20 °C; 5 μL of the ellagic acid stock solution was mixed with 995 μL of OP50 bacterial suspension to obtain a mixture of ellagic acid with a final concentration of 200 μM, in which the concentration of DMSO was 0.5% (v / v), and the mixture was uniformly spread on the surface of NGM medium to obtain NGM medium containing 200 μM ellagic acid. In addition, 5 μL of DMSO solution was mixed with 995 μL of OP50 bacterial suspension to obtain a DMSO solution with a final concentration of 0.5% (v / v), and the solution was uniformly spread on the surface of NGM medium to obtain NGM medium containing 0.5% DMSO.
[0031] To evaluate the ionizing radiation protection effect of ellagic acid, the experiment was set up into five groups, respectively including: ① Control group (unirradiated C. elegans was transferred to NGM medium containing 0.5% DMSO treatment and cultured, and the NGM medium was replaced every other day); ② 20 Gy irradiation group (C. elegans exposed to 20 Gy ionizing radiation was transferred to NGM medium containing 0.5% DMSO treatment and cultured, and the NGM medium was replaced every other day); ③ 20 Gy-200 μM ellagic acid group (C. elegans exposed to 20 Gy ionizing radiation was transferred to NGM medium containing 200 μM ellagic acid treatment and cultured, and the NGM medium was replaced every other day); ④ 50 Gy irradiation group (C. elegans exposed to 50 Gy ionizing radiation was transferred to NGM medium containing 0.5% DMSO treatment and cultured, and the NGM medium was replaced every other day); ⑤ 50 Gy-200 μM ellagic acid group (C. elegans exposed to 50 Gy ionizing radiation was transferred to NGM medium containing 200 μM ellagic acid treatment and cultured, and the NGM medium was replaced every other day).
[0032] 2.4 Determination of reactive oxygen species content On the first day of the adult stage, the reactive oxygen species (ROS) levels in *C. elegans* from the experimental groups were quantitatively analyzed using a reactive oxygen species (ROS) fluorescent probe. Each group contained at least 30 *C. elegans* samples. Specifically, *C. elegans* from the first day of adulthood were collected, washed with M9 buffer, and transferred to 1.5 mL centrifuge tubes. The *C. elegans* were incubated with 1 μM of the ROS fluorescent probe 5′,6′-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) at 20°C for 3 hours. After incubation, the *C. elegans* were washed three times with M9 buffer and then transferred to a 2% agarose mat. Fluorescence was detected using a fluorescence microscope, and the fluorescence images were analyzed using ImageJ image analysis software. The ROS content in each group of *C. elegans* was calculated, and the differences between groups were statistically analyzed.
[0033] 2.5 Detection Experiment of Malondialdehyde Content and Antioxidant Enzyme Activity On the first day of the adult stage, the malondialdehyde (MDA) content, glutathione S-transferase (GST) activity, and superoxide dismutase (SOD) activity in *C. elegans* from the experimental groups were quantitatively analyzed using a malondialdehyde (MDA) content assay kit, a glutathione S-transferase (GST) activity assay kit, and a superoxide dismutase (SOD) activity assay kit. Specifically, *C. elegans* from the experimental groups were collected, washed with M9 buffer, transferred to 1.5 mL centrifuge tubes, homogenized on ice, and centrifuged at 7000 × g for 10 minutes at 4°C. The supernatant was collected for subsequent analysis. The results were standardized based on the total protein concentration in the supernatant, which was determined using a BCA protein quantification kit.
[0034] 2.6 Primer Design and Synthesis According to information published in GenBank sod-1 , sod-2 , gst-1 , gst-29 , lys-1 , irg-1 , irg-2 as well as mul- 1 Gene sequence, with act-1 The genes were used as internal controls. Primers for the above nine genes were designed using Premier 3.0 and were sent to Sangon Biotech (Shanghai) Co., Ltd. for synthesis. Primer information is shown in Table 1.
[0035] Table 1 qRT-PCR primer information
[0036] 2.7 Detection of expression of antioxidant and immune genes On the first day of the adult stage, *C. elegans* samples from the above experimental groups were collected, washed with M9 buffer, and transferred to 1.5 mL centrifuge tubes. Total RNA was extracted from the *C. elegans* samples from different experimental groups using Trizol reagent. Following the experimental method described in the reverse transcription kit, the corresponding cDNA was obtained through reverse transcription. Using the cDNA as a template, a Roche 480 real-time quantitative PCR system was used to detect... sod-1 , sod-2 , gst-1 , gst-29 , lys-1 , irg-1 , irg-2 as well as mul-1 Gene expression levels in different experimental groups. This experiment used... act-1 As an internal reference gene, the relative value of the gene was calculated using the 2^-∆∆Ct method. act-1 Gene expression levels.
[0037] 2.8 Stress Tolerance Test On the fifth day of the adult stage, *C. elegans* samples from the above experimental groups were collected, washed three times with M9 buffer, and transferred to 24-well plates. *C. elegans* S liquid medium containing the following stressors (osmotic stress: 200 mM NaCl; metal pressure stress: 50 mM cadmium chloride; oxidative stress: 100 µM juglone) was added to the 24-well plates. Sixty *C. elegans* were randomly selected from each experimental group, and the number of surviving *C. elegans* was recorded every 30 minutes until all worms died.
[0038] For pathogen resistance experiments, *Pseudomonas aeruginosa* was inoculated onto 90 mm NGM medium and incubated at 37°C for 24 hours. The culture was then transferred to room temperature for equilibration for 24 hours to allow the formation of a bacterial flora. Then, on the fifth day of the adult stage, 60 *C. elegans* samples from the above experimental groups were transferred to the center of NGM medium containing the *Pseudomonas aeruginosa* bacterial flora and incubated at 20°C throughout the process. Survival rates were measured every 12 hours from 24 to 108 hours post-infection by mechanical stimulation response. Those without a response were considered dead, and the mortality rate was calculated as a percentage of the initial *C. elegans* sample size.
[0039] 2.9 Lifetime Experiment Based on the above experimental treatment group divisions, approximately 100-150 L1-stage *C. elegans* worms were transferred to the corresponding NGM medium in each experimental group, and the survival status of the *C. elegans* was monitored daily, i.e., their life status was distinguished as alive, dead, or lost using a stereomicroscope. In this experiment, the larval stage was defined as day 1 of the *C. elegans* life cycle, and survival curves and average lifespan of *C. elegans* were plotted.
[0040] 2.10 Data Processing All experiments were set up in triplicate, and data were plotted and analyzed using GraphPad Prism 9.5.1. The results of the stressor tolerance experiment were expressed as the mean ± standard error, and the rest of the data were expressed as the mean ± standard deviation; p <0.05 was considered statistically significant; represented by “*”: p <0.05, represented by “**”: p <0.01, represented by “***”: p <0.001.
[0041] 3. Results and analysis 3.1 Ellagic acid alleviates oxidative damage in C. elegans under ionizing radiation exposure In this experiment, the CM-H2DCFDA fluorescent probe was used to identify the content of reactive oxygen species in C. elegans, and the results are shown in Figure 1 A. Quantitative analysis of reactive oxygen species levels showed that, compared with the control group, the reactive oxygen species levels in the 20 Gy and 50 Gy irradiation groups were significantly increased; compared with the 20 Gy and 50 Gy irradiation groups, the reactive oxygen species levels in the 20 Gy-200 μM ellagic acid group and the 50 Gy-200 μM ellagic acid group were significantly reduced.
[0042] Further, in this experiment, the content of malondialdehyde, the activities of superoxide dismutase and glutathione transferase in C. elegans were quantitatively analyzed by using related kits, and the results are shown in Figure 1 B-D. Quantitative analysis of malondialdehyde levels showed that, compared with the control group, the malondialdehyde levels in the 20 Gy and 50 Gy irradiation groups were significantly increased; compared with the 20 Gy and 50 Gy irradiation groups, the malondialdehyde levels in the 20 Gy-200 μM ellagic acid group and the 50 Gy-200 μM ellagic acid group were significantly reduced and returned to the control group level. According to Figure 1 C and Figure 1 D, quantitative analysis of antioxidant enzyme activity (glutathione transferase activity and superoxide dismutase activity) showed that, compared with the control group, the antioxidant enzyme activity in the 20 Gy and 50 Gy irradiation groups was significantly inhibited; compared with the 20 Gy and 50 Gy irradiation groups, the antioxidant enzyme activity in the 20 Gy-200 μM ellagic acid group and the 50 Gy-200 μM ellagic acid group was significantly increased and significantly higher than the control group level.
[0043] In addition, the antioxidant genes (sod-1, sod-3, gst-4 and gst-21) in C. elegans were also determined in this experiment. sod-1 , sod-2 , gst-1 and gst-29 The expression is as follows: Figure 1 E to Figure 1 As shown in Figure H, qRT-PCR results indicated that, compared with the control group, the expression of antioxidant genes in *C. elegans* in the 20 Gy and 50 Gy irradiation groups remained essentially unchanged. Compared with the 20 Gy and 50 Gy irradiation groups, the expression of antioxidant genes in *C. elegans* in the 20 Gy-200 μM ellagic acid group and the 50 Gy-200 μM ellagic acid group was significantly increased, and significantly higher than the control group.
[0044] The above results indicate that 200 μM ellagic acid can significantly improve the activity and gene expression of antioxidant enzymes, reduce the excessive accumulation of reactive oxygen species and lipid peroxidation levels, which suggests that an effective concentration of ellagic acid can alleviate oxidative damage in *C. elegans* caused by ionizing radiation exposure.
[0045] 3.2 Ellagic acid enhances the immune response of *C. elegans* under ionizing radiation exposure. This experiment determined the immune genes of Caenorhabditis elegans (C. elegans). lys-1 , irg-1 , irg-2 as well as mul-1 The expression is as follows: Figure 2 As shown in the figure. qRT-PCR results indicated that, compared with the control group, the expression of immune response genes in *C. elegans* in the 20 Gy irradiation group and the 50 Gy irradiation group remained essentially unchanged or significantly downregulated. Compared with the 20 Gy irradiation group and the 50 Gy irradiation group, the expression of immune response genes in *C. elegans* was significantly increased in the 20 Gy-200 μM ellagic acid group and the 50 Gy-200 μM ellagic acid group, and significantly higher than the control group. This result indicates that 200 μM ellagic acid can activate the immune response in *C. elegans*.
[0046] 3.3 Ellagic acid inhibits the decrease in stress tolerance of Caenorhabditis elegans under ionizing radiation exposure. This experiment tested the tolerance of *C. elegans* to four stressors: oxidative stress, osmotic pressure, metal pressure, and *Pseudomonas aeruginosa*. The results are as follows: Figure 3 As shown in the figure. Experimental results indicated that, compared to the control group, the tolerance of *C. elegans* to the four stressors was significantly reduced in the 20 Gy and 50 Gy irradiation groups. Compared to the 20 Gy and 50 Gy irradiation groups, the tolerance of *C. elegans* to the four stressors was significantly enhanced in the 20 Gy-200 μM ellagic acid and 50 Gy-200 μM ellagic acid groups, returning to the control group levels. This result demonstrates that 200 μM ellagic acid can significantly inhibit the reduction in multiple stress tolerances in *C. elegans* induced by ionizing radiation exposure.
[0047] 3.4 Role of ellagic acid in restoring the shortened lifespan of C. elegans induced by ionizing radiation exposure The lifespan of C. elegans was detected in the experiment, and the results are shown in Figure 4 The lifespan experiment results show that, compared with the control group, the lifespan of C. elegans in the 20Gy and 50Gy irradiation groups is significantly shortened, and the average lifespan is shortened by 17.79% and 24.50%, respectively; compared with the 20Gy and 50Gy irradiation groups, the lifespan of C. elegans in the 20 Gy-200 μM ellagic acid group and the 50 Gy-200 μM ellagic acid group is significantly prolonged and restored to the level of the control group.
[0048] From the above examples, it can be seen that, after ionizing radiation exposure of C. elegans, the effective concentration of ellagic acid is given for treatment, and the results show that: compared with the ionizing radiation group, the effective concentration of ellagic acid can enhance the expression of antioxidant genes, thereby enhancing the activities of glutathione transferase and superoxide dismutase, reducing the excessive accumulation of ROS in C. elegans induced by ionizing radiation, and reducing the level of lipid peroxidation marker malondialdehyde, thereby inhibiting lipid peroxidation damage. At the same time, ellagic acid promotes the expression of immune-related genes, effectively inhibits the decrease of stress tolerance, and restores the shortened lifespan induced by ionizing radiation. In summary, the effective concentration of ellagic acid treatment can significantly alleviate the damage and health risks of ionizing radiation, and can be used for ionizing radiation protection.
[0049] The above is only one specific embodiment of the present application, which is described in more detail and in detail, but should not be construed as limiting the scope of patent protection of the present application. Any skilled person in the art can make equivalent replacements or changes to the technical scope disclosed in the present application according to the technical solution and inventive concept of the present application, which should be covered within the protection scope of the present application.
Claims
1. Use of ellagic acid in the preparation of a medicament for preventing or treating ionizing radiation damage.
2. Use according to claim 1, characterized in that, The ionizing radiation includes X-ray, α-ray irradiation, β-ray irradiation, γ-ray irradiation, neutron and heavy ion radiation.
3. Use according to claim 1, characterized in that, The ionizing radiation damage includes ionizing radiation-induced oxidative damage, inflammatory response, decreased stress tolerance, accelerated aging and shortened lifespan.
4. Use according to claim 1, characterized in that, The medicament includes an effective amount of the above-mentioned ellagic acid and pharmaceutically acceptable adjuvants.
5. Use according to claim 4, characterized in that, The pharmaceutically acceptable adjuvants include fillers, diluents, binders, disintegrants and emulsifiers.
6. Use according to claim 1, characterized in that, The medicament is prepared into a pharmaceutically allowable dosage form.
7. Use according to claim 6, characterized in that, The dosage form includes tablets, granules, oral liquid preparations, drops, injection preparations and capsule preparations.
8. The use according to claim 2, characterized in that, The medicine relieves oxidative damage, inflammatory response, stress tolerance decrease, aging acceleration and life shortening caused by ionizing radiation exposure by eliminating active oxygen, inhibiting lipid peroxidation, enhancing glutathione transferase activity and superoxide dismutase activity, and promoting expression of antioxidant-related genes sod-1 、 sod-2 、 gst-1 and gst-29 and immune-related genes lys-1 、 irg-1 、 irg-2 and mul-1 .
9. The use according to claim 1, characterized in that, The medicament containing an effective concentration of ellagic acid is administered to a subject before ionizing radiation exposure or after ionizing radiation exposure.
10. The use according to claim 1, characterized in that, The medicament is used for nuclear accident emergency radiation protection, adjuvant therapy for secondary damage effects of radiotherapy patients and space radiation protection of astronauts.